Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Metastatic Renal Cell Carcinoma Overview 10 Therapeutics Development 11 Pipeline Products for Metastatic Renal Cell Carcinoma - Overview 11 Pipeline Products for Metastatic Renal Cell Carcinoma - Comparative Analysis 12 Metastatic Renal Cell Carcinoma - Therapeutics under Development by Companies 13 Metastatic Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 17 Metastatic Renal Cell Carcinoma - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Metastatic Renal Cell Carcinoma - Products under Development by Companies 22 Metastatic Renal Cell Carcinoma - Products under Investigation by Universities/Institutes 25 Metastatic Renal Cell Carcinoma - Companies Involved in Therapeutics Development 26 Acceleron Pharma, Inc. 26 Amgen Inc. 27 Argos Therapeutics, Inc. 28 Astellas Pharma Inc. 29 Bayer AG 30 Beta Pharma, Inc. 31 Bionomics Limited 32 Bionovis SA 33 Bristol-Myers Squibb Company 34 Cellceutix Corporation 35 Celldex Therapeutics, Inc. 36 Cerulean Pharma, Inc. 37 Dr. Reddy's Laboratories Limited 38 EirGenix Inc. 39 Eisai Co., Ltd. 40 Eli Lilly and Company 41 Epirus Biopharmaceuticals, Inc. 42 Exelixis, Inc. 43 Genor BioPharma Co., Ltd. 44 GlaxoSmithKline Plc 45 Hospira, Inc. 46 Immatics Biotechnologies GmbH 47 Immune Design Corp. 48 Immunicum AB 49 Inbiopro Solutions Pvt. Ltd. 50 Mabion SA 51 Merck & Co., Inc. 52 Millennium Pharmaceuticals, Inc. 53 Mycenax Biotech Inc. 54 NewLink Genetics Corporation 55 Novartis AG 56 Oncobiologics, Inc. 57 Ono Pharmaceutical Co., Ltd. 58 Panacea Biotec Limited 59 Peloton Therapeutics, Inc. 60 Prima BioMed Ltd. 61 Rexahn Pharmaceuticals, Inc. 62 Seattle Genetics, Inc. 63 Sevion Therapeutics, Inc. 64 Syndax Pharmaceuticals, Inc. 65 Tocagen Inc. 66 TVAX Biomedical, Inc. 67 Metastatic Renal Cell Carcinoma - Therapeutics Assessment 68 Assessment by Monotherapy Products 68 Assessment by Combination Products 69 Assessment by Target 70 Assessment by Mechanism of Action 77 Assessment by Route of Administration 81 Assessment by Molecule Type 83 Drug Profiles 85 AGS-16C3F - Drug Profile 85 aldesleukin - Drug Profile 86 archexin - Drug Profile 87 bevacizumab biosimilar - Drug Profile 89 bevacizumab biosimilar - Drug Profile 90 bevacizumab biosimilar - Drug Profile 92 bevacizumab biosimilar - Drug Profile 93 bevacizumab biosimilar - Drug Profile 94 bevacizumab biosimilar - Drug Profile 95 bevacizumab biosimilar - Drug Profile 96 bevacizumab biosimilar - Drug Profile 97 bevacizumab biosimilar - Drug Profile 98 bevacizumab biosimilar - Drug Profile 99 bevacizumab biosimilar - Drug Profile 100 bevacizumab biosimilar - Drug Profile 101 BNC-105 - Drug Profile 102 BPI-3119 - Drug Profile 105 cabozantinib s-malate - Drug Profile 106 capmatinib - Drug Profile 110 Cellular Immunotherapy for Metastatic Renal Cell Carcinoma - Drug Profile 113 Cellular Immunotherapy for Metastatic Renal Cell Carcinoma and Melanoma - Drug Profile 114 CRLX-101 - Drug Profile 115 dalantercept - Drug Profile 118 emibetuzumab - Drug Profile 120 entinostat - Drug Profile 121 flucytosine ER + vocimagene amiretrorepvec - Drug Profile 125 G-305 - Drug Profile 128 IBPM-002BZ - Drug Profile 130 IMA-901 - Drug Profile 131 IMP-321 - Drug Profile 133 Intuvax - Drug Profile 135 ipilimumab - Drug Profile 139 KM-3174 - Drug Profile 144 lenvatinib mesylate - Drug Profile 148 LY-2510924 - Drug Profile 154 Monoclonal Antibody Conjugate to Target G250 Antigen for Renal Cell Carcinoma - Drug Profile 156 nivolumab - Drug Profile 157 Orellanine - Drug Profile 165 panobinostat - Drug Profile 166 pazopanib hydrochloride + pembrolizumab - Drug Profile 173 pembrolizumab - Drug Profile 174 PT-2385 - Drug Profile 184 radium Ra 223 dichloride - Drug Profile 185 Recombinant Protein for Oncology - Drug Profile 188 rocapuldencel-t - Drug Profile 189 sapanisertib - Drug Profile 192 SGN-CD70A - Drug Profile 194 SNX-5422 - Drug Profile 195 SVN-002 - Drug Profile 197 trebananib - Drug Profile 198 TVI-Kidney-1 - Drug Profile 201 varlilumab - Drug Profile 202 Metastatic Renal Cell Carcinoma - Recent Pipeline Updates 205 Metastatic Renal Cell Carcinoma - Dormant Projects 321 Metastatic Renal Cell Carcinoma - Discontinued Products 326 Metastatic Renal Cell Carcinoma - Product Development Milestones 327 Featured News & Press Releases 327 Appendix 336 Methodology 336 Coverage 336 Secondary Research 336 Primary Research 336 Expert Panel Validation 336 Contact Us 336 Disclaimer 337

List of Tables Number of Products under Development for Metastatic Renal Cell Carcinoma, H1 2016 14 Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H1 2016 15 Number of Products under Development by Companies, H1 2016 17 Number of Products under Development by Companies, H1 2016 (Contd..1) 18 Number of Products under Development by Companies, H1 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H1 2016 20 Comparative Analysis by Late Stage Development, H1 2016 21 Comparative Analysis by Clinical Stage Development, H1 2016 22 Comparative Analysis by Early Stage Development, H1 2016 23 Comparative Analysis by Unknown Stage Development, H1 2016 24 Products under Development by Companies, H1 2016 25 Products under Development by Companies, H1 2016 (Contd..1) 26 Products under Development by Companies, H1 2016 (Contd..2) 27 Products under Investigation by Universities/Institutes, H1 2016 28 Metastatic Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H1 2016 29 Metastatic Renal Cell Carcinoma - Pipeline by Amgen Inc., H1 2016 30 Metastatic Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H1 2016 31 Metastatic Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H1 2016 32 Metastatic Renal Cell Carcinoma - Pipeline by Bayer AG, H1 2016 33 Metastatic Renal Cell Carcinoma - Pipeline by Beta Pharma, Inc., H1 2016 34 Metastatic Renal Cell Carcinoma - Pipeline by Bionomics Limited, H1 2016 35 Metastatic Renal Cell Carcinoma - Pipeline by Bionovis SA, H1 2016 36 Metastatic Renal Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 37 Metastatic Renal Cell Carcinoma - Pipeline by Cellceutix Corporation, H1 2016 38 Metastatic Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 39 Metastatic Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H1 2016 40 Metastatic Renal Cell Carcinoma - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 41 Metastatic Renal Cell Carcinoma - Pipeline by EirGenix Inc., H1 2016 42 Metastatic Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H1 2016 43 Metastatic Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H1 2016 44 Metastatic Renal Cell Carcinoma - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 45 Metastatic Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H1 2016 46 Metastatic Renal Cell Carcinoma - Pipeline by Genor BioPharma Co., Ltd., H1 2016 47 Metastatic Renal Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H1 2016 48 Metastatic Renal Cell Carcinoma - Pipeline by Hospira, Inc., H1 2016 49 Metastatic Renal Cell Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H1 2016 50 Metastatic Renal Cell Carcinoma - Pipeline by Immune Design Corp., H1 2016 51 Metastatic Renal Cell Carcinoma - Pipeline by Immunicum AB, H1 2016 52 Metastatic Renal Cell Carcinoma - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2016 53 Metastatic Renal Cell Carcinoma - Pipeline by Mabion SA, H1 2016 54 Metastatic Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H1 2016 55 Metastatic Renal Cell Carcinoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 56 Metastatic Renal Cell Carcinoma - Pipeline by Mycenax Biotech Inc., H1 2016 57 Metastatic Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H1 2016 58 Metastatic Renal Cell Carcinoma - Pipeline by Novartis AG, H1 2016 59 Metastatic Renal Cell Carcinoma - Pipeline by Oncobiologics, Inc., H1 2016 60 Metastatic Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 61 Metastatic Renal Cell Carcinoma - Pipeline by Panacea Biotec Limited, H1 2016 62 Metastatic Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H1 2016 63 Metastatic Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H1 2016 64 Metastatic Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016 65 Metastatic Renal Cell Carcinoma - Pipeline by Seattle Genetics, Inc., H1 2016 66 Metastatic Renal Cell Carcinoma - Pipeline by Sevion Therapeutics, Inc., H1 2016 67 Metastatic Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016 68 Metastatic Renal Cell Carcinoma - Pipeline by Tocagen Inc., H1 2016 69 Metastatic Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H1 2016 70 Assessment by Monotherapy Products, H1 2016 71 Assessment by Combination Products, H1 2016 72 Number of Products by Stage and Target, H1 2016 74 Number of Products by Stage and Mechanism of Action, H1 2016 81 Number of Products by Stage and Route of Administration, H1 2016 85 Number of Products by Stage and Molecule Type, H1 2016 87 Metastatic Renal Cell Carcinoma Therapeutics - Recent Pipeline Updates, H1 2016 208 Metastatic Renal Cell Carcinoma - Dormant Projects, H1 2016 324 Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..1), H1 2016 325 Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..2), H1 2016 326 Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..3), H1 2016 327 Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..4), H1 2016 328 Metastatic Renal Cell Carcinoma - Discontinued Products, H1 2016 329 List of Figures Number of Products under Development for Metastatic Renal Cell Carcinoma, H1 2016 14 Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H1 2016 15 Number of Products under Development by Companies, H1 2016 16 Number of Products under Investigation by Universities/Institutes, H1 2016 20 Comparative Analysis by Late Stage Development, H1 2016 21 Comparative Analysis by Clinical Stage Development, H1 2016 22 Comparative Analysis by Early Stage Products, H1 2016 23 Assessment by Monotherapy Products, H1 2016 71 Assessment by Combination Products, H1 2016 72 Number of Products by Top 10 Targets, H1 2016 73 Number of Products by Stage and Top 10 Targets, H1 2016 73 Number of Products by Top 10 Mechanism of Actions, H1 2016 80 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 80 Number of Products by Routes of Administration, H1 2016 84 Number of Products by Stage and Routes of Administration, H1 2016 84 Number of Products by Top 10 Molecule Types, H1 2016 86 Number of Products by Stage and Top 10 Molecule Types, H1 2016 86

Acceleron Pharma, Inc. Amgen Inc. Argos Therapeutics, Inc. Astellas Pharma Inc. Bayer AG Beta Pharma, Inc. Bionomics Limited Bionovis SA Bristol-Myers Squibb Company Cellceutix Corporation Celldex Therapeutics, Inc. Cerulean Pharma, Inc. Dr. Reddy's Laboratories Limited EirGenix Inc. Eisai Co., Ltd. Eli Lilly and Company Epirus Biopharmaceuticals, Inc. Exelixis, Inc. Genor BioPharma Co., Ltd. GlaxoSmithKline Plc Hospira, Inc. Immatics Biotechnologies GmbH Immune Design Corp. Immunicum AB Inbiopro Solutions Pvt. Ltd. Mabion SA Merck & Co., Inc. Millennium Pharmaceuticals, Inc. Mycenax Biotech Inc. NewLink Genetics Corporation Novartis AG Oncobiologics, Inc. Ono Pharmaceutical Co., Ltd. Panacea Biotec Limited Peloton Therapeutics, Inc. Prima BioMed Ltd. Rexahn Pharmaceuticals, Inc. Seattle Genetics, Inc. Sevion Therapeutics, Inc. Syndax Pharmaceuticals, Inc. Tocagen Inc. TVAX Biomedical, Inc.